



Building Resistance to AMR

► AMR Alliance Japan is Working to Combat Antimicrobial Resistance

Antimicrobial Resistance (AMR) refers to the phenomena by which bacteria become immune to antimicrobial treatments over time as those treatments are used more and more. Infectious diseases caused by antimicrobial resistant bacteria can be difficult to treat, or even fatal in worst case scenarios. As a multi-stakeholder alliance of government, academia, civil society, and private sector members, AMR Alliance Japan works with its domestic and foreign partners to promote policies that strengthen AMR countermeasures.

From 2018-2023, antimicrobial resistance rose in over 40% of monitored infections.

In 2023, 1 in 6 bacterial infections worldwide were resistant to antibiotics.

Between 2025-2050, AMR could cause 39 million deaths - 3 deaths every minute.

Without decisive action, more people will die from AMR, failing to meet the 2030 global goal of reducing deaths by 10%.

► About AMR Alliance Japan

Established in November 2018 by academic societies working in infectious disease medicine, pharmaceutical companies, and medical device makers, AMR Alliance Japan is an independent platform for the promotion of multisector discussion on AMR countermeasures. AMR Alliance Japan works to 1) realize AMR countermeasures in line with the current situation faced by medical practitioners and patients; 2) promote the AMR policy agenda domestically and abroad; and 3) create and promote policy recommendations on the actions expected of Japan on AMR.

► Current Members (in alphabetical order, as of January, 2026):

bioMérieux Japan Ltd., GlaxoSmithKline K.K., Himeji City, Japan Medical Association, Japan Pharmaceutical Association, Japan Pharmaceutical Manufacturers Association, Japanese Society for Pediatric Infectious Diseases, Japanese Society of Antimicrobials for Animals, Japanese Society of Chemotherapy, Japanese Society of Hospital Pharmacists, “Kodomo to Iryo” Project, Meiji Seika Pharma Co., Ltd., Merck & Co., Inc., Nippon Becton, Dickinson and Company, Ltd., Pfizer Japan Inc., Shimadzu Diagnostics Corporation, Shionogi & Co., Ltd., The Japanese Society for Medical Mycology, The Japanese Association for Infectious Diseases, The Japanese Society for Clinical Microbiology, The Japanese Society for Infection Prevention and Control, The Japanese Society of Pharmaceutical Health Care and Sciences, The Japanese Society of Therapeutic Drug Monitoring, The Pharmaceutical Society of Japan, Health and Global Policy Institute (HGPI) serves as Secretariat of the Alliance.



► About the Alliance’s Policy Recommendations

On July 11, 2019, AMR Alliance Japan announced “AMR Alliance Japan Policy Recommendations: The Japanese Government’s Role in Promoting AMR Countermeasures.” The themes of the policy recommendations are as follows.

- Promoting antimicrobial stewardship based on the actual situation at healthcare facilities
- Constructing domestic AMR surveillance and crisis management systems
- Enabling the further and active use of AMR screening methods and rapid diagnostic technology
- Supporting education on AMR for the public and medical practitioners
- Establishing incentive models to encourage R&D for antimicrobials
- Stabilizing the supply of antimicrobials
- International collaborations to share case studies and lessons learned on AMR domestically and abroad



► Recent Activities

| | |
|--------------------|---|
| November 08, 2018 | Global Expert Meeting to Commemorate the Establishment of AMR Alliance Japan |
| July 11, 2019 | Recommendations - The Japanese Government’s Role in Promoting AMR Countermeasures (AMR Alliance Japan) |
| October 3, 2019 | AMR Alliance Japan Delivered Policy Recommendations on AMR to Minister of Health, Labour and Welfare, Katsunobu Kato |
| November 20, 2020 | New Policy Briefs on the Situation of AMR in Japan and Abroad |
| March 24, 2021 | Recommendations - Creating Pull Incentives for Antimicrobials (Secretariat: AMR Alliance Japan. Part of the Nikkei FT Communicable Diseases Conference Asia Africa Medical Innovation Consortium) |
| May 30, 2022 | Urgent Recommendation - the Basic Policy on Economic and Fiscal Management and Reform 2022 |
| August 18, 2022 | HGPI Special Seminar “Universal Health Coverage in an Era of Antimicrobial Resistance” |
| November 10, 2022 | AMR Alliance Japan Delivered Policy Recommendations on AMR to Minister of Health, Labour and Welfare, Katsunobu Kato and Minister of Foreign Affairs, Yoshimasa Hayashi |
| December 19, 2022 | Recommendations - The Political Leadership and International Collaboration Needed to Advance Antimicrobial Resistance (AMR) Countermeasures |
| February 28, 2023 | AMR Special Symposium “Reframing AMR as the Infrastructure Guarding the World: Building Multi-Stakeholder Commitment to the One Health Approach Looking to the G7, UNGA, and Beyond” |
| April 28, 2023 | Recommendations to Prime Minister Fumio Kishida on the issue of antimicrobial resistance (AMR) in the G7 Hiroshima Summit Leaders’ Declaration |
| September 25, 2024 | UN General Assembly High-Level Meeting on AMR Side Event “Global Action on AMR: Advancing Healthy Longevity and Sustainability under UHC” |



AMR Alliance Japan
Website



HGPI Health and Global
Policy Institute



Secretariat: Health and Global Policy Institute
Grand Cube 3F, Otemachi Financial City, Global Business Hub
Tokyo1-9-2, Otemachi, Chiyoda-ku, Tokyo 100-0004 JAPAN
TEL: +81-3-4243-7156 FAX: +81-3-4243-7378
Mail: info@hgpi.org Website: <https://www.hgpi.org/en/>

Copyright © 2026 Health and Global Policy Institute All rights reserved.